SUMATRAN

This brand name is authorized in Australia, Ireland, Singapore

Active ingredients

The drug SUMATRAN contains one active pharmaceutical ingredient (API):

1 Sumatriptan UNII J8BDZ68989 - SUMATRIPTAN SUCCINATE

Sumatriptan has been demonstrated to be a specific and selective 5-Hydroxytryptamine1 (5HT1D) receptor agonist with no effect on other 5HT receptor (5-HT2 - 5-HT7) subtypes. The vascular 5-HT1D receptor is found predominantly in cranial blood vessels and mediates vasoconstriction. Read about Sumatriptan

Medication package inserts

Below package inserts are available for further reading:

Title	Information Source	Document Type
SUMATRAN Tablet	Health Products Regulatory Authority (IE)	MPI, EU: SmPC

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
N02CC01	Sumatriptan	N Nervous system → N02 Analgesics → N02C Antimigraine preparations → N02CC Selective serotonin (5HT1) agonists
Discover more medicines within N02CC01

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: AU	Pharmaceutical Benefits Scheme	Identifier(s): 1849H, 8144P
Country: IE	Health Products Regulatory Authority	Identifier(s): 68345, 68359, 68374
Country: SG	Health Sciences Authority	Identifier(s): 13667P